Full Year 2022 GAAP Revenue increased 22% to $861 million
Full Year 2022 GAAP Net Income of $74 million
Full Year 2022 GAAP Diluted Earnings Per Share increased 46% to $2.06
Full Year 2022 Adjusted Earnings Per Share increased 17% to $3.07
Full Year 2022 Adjusted EBITDA of $184 million
BEDFORD, Mass.–(BUSINESS WIRE)–Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the fourth quarter and full year 2022.
Financial Highlights
Three Months Ended December 31,
Year Ended December 31,
(In millions, except per share amounts)
2022
2021
2022
2021
GAAP
Revenue
$
218.4
$
199.0
$
860.9
$
706.8
Operating Income
$
26.8
$
21.7
$
103.1
$
64.1
Net Income
$
15.3
$
13.8
$
74.1
$
50.3
Diluted EPS
$
0.42
$
0.38
$
2.06
$
1.41
Non-GAAP*
Adjusted Operating Income
$
37.3
$
33.9
$
147.5
$
116.9
Adjusted Diluted EPS
$
0.75
$
0.67
$
3.07
$
2.62
Adjusted EBITDA
$
46.1
$
42.6
$
184.1
$
152.7
*Reconciliations of GAAP to non-GAAP financial measures, as well as definitions for the non-GAAP financial measures included in this press release and the reasons for their use, are presented below.
“Novanta delivered record financial results for 2022,” said Matthijs Glastra, Chair and Chief Executive Officer of Novanta. “In the fourth quarter, our teams continued to execute well, delivering impressive performance in a challenging operating environment, delivering strong revenue and profit growth for the quarter and for the full year.”
Matthijs Glastra continued, “Looking at 2023 and beyond, we intend to continue to focus on new product development, design wins in high growth applications, driving cash flows, and institutionalizing the Novanta Growth System. With leading and diverse technologies across attractive high growth markets, we believe Novanta is well positioned to continue to deliver sustained long-term shareholder value.”
Fourth Quarter
During the fourth quarter of 2022, Novanta generated GAAP revenue of $218.4 million, an increase of $19.4 million, or 9.8%, versus the fourth quarter of 2021. The Company’s acquisition activities resulted in an increase in revenue of $3.2 million, or 1.6%, compared to the fourth quarter of 2021. Changes in foreign currency exchange rates year over year adversely impacted our revenue by $11.3 million, or 5.6%, during the fourth quarter of 2022. Our year-over-year Organic Revenue Growth, which excludes the net impact of acquisitions and changes in foreign currency exchange rates, was an increase of 13.8% for the fourth quarter of 2022 (see “Organic Revenue Growth” in the non-GAAP reconciliations below).
In the fourth quarter of 2022, GAAP operating income was $26.8 million, compared to $21.7 million in the fourth quarter of 2021. GAAP net income was $15.3 million in the fourth quarter of 2022, compared to $13.8 million in the fourth quarter of 2021. GAAP diluted earnings per share (“EPS”) was $0.42 in the fourth quarter of 2022, compared to $0.38 in the fourth quarter of 2021.
Adjusted Diluted EPS was $0.75 in the fourth quarter of 2022, compared to $0.67 in the fourth quarter of 2021. The Company ended the fourth quarter of 2022 with 36.0 million diluted weighted average shares outstanding. Adjusted EBITDA was $46.1 million in the fourth quarter of 2022, compared to $42.6 million in the fourth quarter of 2021.
Operating cash flow for the fourth quarter of 2022 was $40.6 million, compared to $28.7 million for the fourth quarter of 2021.
Full Year
For the full year 2022, Novanta generated GAAP revenue of $860.9 million, an increase of $154.1 million, or 21.8%, versus the full year 2021. The Company’s acquisition activities resulted in an increase in revenue of $93.3 million, or 13.2%. Changes in foreign currency exchange rates year over year favorably impacted our revenue by $36.9 million, or 5.2%, in 2022. Our year-over-year Organic Revenue Growth, which excludes the net impact of acquisitions and changes in foreign currency exchange rates, was an increase of 13.8% for the full year 2022 (see “Organic Revenue Growth” in Reconciliation of GAAP to Non-GAAP Financial Measures below).
For the full year 2022, GAAP operating income was $103.1 million, compared to $64.1 million for 2021. GAAP net income was $74.1 million for the full year 2022, compared to $50.3 million for 2021. GAAP diluted EPS was $2.06 for the full year 2022, compared to $1.41 for 2021.
Adjusted Diluted EPS was $3.07 for the full year 2022, compared to $2.62 for 2021. For the full year 2022, the Company had 35.9 million diluted weighted average shares outstanding. Adjusted EBITDA was $184.1 million for the full year 2022, compared to $152.7 million for 2021.
Operating cash flow for the full year 2022 was $90.8 million, compared to $94.6 million for 2021. The Company finished the year with approximately $435.5 million of total debt and $100.1 million of total cash. Net Debt, as defined in the non-GAAP reconciliation below, was $340.2 million.
Financial Guidance
“We remain very optimistic about our position and opportunities in the medical and advanced industrial end markets that we serve,” said Matthijs Glastra, “Sales in our medical end markets are expected to have solid demand in 2023. And despite some near term slowdown in some areas of the microelectronics end market capital spending, we enter the year with strong backlog and resilient customer demand. We are confident in the ability of our teams to remain disciplined and diligent to serve our customers and deliver strong operating performance in the year ahead.”
For the first quarter of 2023, the Company expects GAAP revenue of approximately $210 million to $212 million. The Company expects Adjusted EBITDA to be in the range of $44 million to $45 million and Adjusted Diluted EPS to be in the range of $0.64 to $0.65. The Company’s guidance assumes no significant changes in foreign exchange rates.
For the full year 2023, the Company expects GAAP revenue of approximately $890 million to $915 million. The Company expects Adjusted EBITDA to be in the range of $195 million to $207 million and Adjusted Diluted EPS to be in the range of $3.00 to $3.20. The Company’s guidance assumes no significant changes in foreign exchange rates, but does assume a weighted average interest rate of 6%, and therefore $24 million to $26 million of net interest expense.
Novanta provides earnings guidance on a non-GAAP basis and does not provide earnings guidance on a GAAP basis, with the exception of GAAP revenue guidance. A reconciliation of the Company’s forward-looking Adjusted Gross Profit Margin, Adjusted EBITDA and Adjusted Diluted EPS guidance to the most directly comparable GAAP financial measures is not provided because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including future changes in the fair value of contingent considerations; significant discrete income tax expenses (benefits); divestitures and related expenses; acquisitions and related expenses; impact of purchase price allocations for recently completed acquisitions; gains and losses from sale of real estate assets; costs related to product line closures; intangible asset impairment charges and related asset write-offs; future restructuring expenses; foreign exchange gains/(losses); benefits or expenses associated with the completion of tax audits; and other charges reflected in the Company’s reconciliation of historical non-GAAP financial measures, the amounts of which, based on past experience, could be material. For additional information regarding Novanta’s non-GAAP financial measures, see “Use of Non-GAAP Financial Measures” below.
Conference Call Information
The Company will host a conference call on Wednesday, March 1, 2023 at 10:00 a.m. ET to discuss these results and to provide a business update. To access the call, please dial (888) 346-3959 prior to the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company’s website at www.novanta.com.
A replay of the audio webcast will be available approximately three hours after the conclusion of the call in the Investor Relations section of the Company’s website at www.novanta.com. The replay will remain available until Monday, April 3, 2023.
Use of Non-GAAP Financial Measures
The non-GAAP financial measures used in this press release are Organic Revenue Growth, Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted Operating Income and Operating Margin, Adjusted Income before Income Taxes, Adjusted Income Tax Provision/(Benefit) and Effective Tax Rate, Adjusted Net Income, Adjusted Diluted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Free Cash Flow as a Percentage of Net Income, and Net Debt.
The Company believes that these non-GAAP financial measures provide useful and supplementary information to investors regarding the operating performance of the Company. It is management’s belief that these non-GAAP financial measures would be particularly useful to investors because of the significant changes that have occurred outside of the Company’s day-to-day business in accordance with the execution of the Company’s strategy. This strategy includes streamlining the Company’s existing operations through site and functional consolidations, strategic divestitures and product line closures, expanding the Company’s business through significant internal investments, and broadening the Company’s product and service offerings through acquisition of innovative and complementary technologies and solutions. The financial impact of certain elements of these activities, particularly acquisitions, divestitures, and site and functional restructurings, is often large relative to the Company’s overall financial performance and can adversely affect the comparability of its operating results and investors’ ability to analyze the business from period to period.
The Company’s Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Margin are used by management to evaluate operating performance, communicate financial results to the Board of Directors, benchmark results against historical performance and the performance of peers, and evaluate investment opportunities, including acquisitions and divestitures. In addition, Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Margins are used to determine bonus payments for senior management and employees. The Company also uses Adjusted Diluted EPS as a measurement for certain performance-based restricted stock units issued to certain executives. Accordingly, the Company believes that these non-GAAP financial measures provide greater transparency and insight into management’s method of analysis.
Non-GAAP financial measures should not be considered as substitutes for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on the Company’s reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company’s financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial measures. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.
Safe Harbor and Forward-Looking Information
Certain statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. All statements contained in this news release that do not relate to matters of historical fact should be considered forward-looking statements, and are generally identified by words such as “expect,” “intend,” “anticipate,” “estimate,” “believe,” “future,” “could,” “should,” “plan,” “aim,” and other similar expressions. These forward-looking statements include, but are not limited to, statements regarding anticipated financial performance and financial position, including our financial outlook for the first quarter and full year 2023; expectations for our end markets and market position; expectations regarding our ability to navigate difficult macroeconomic conditions; our ability to deliver sustained long-term shareholder value; expectations regarding our backlog and demand in our medical and advanced industrial end-markets; and other statements that are not historical facts.
These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, but not limited to, the following: economic and political conditions and the effects of these conditions on our customers’ businesses, capital expenditures and level of business activities; risks associated with the COVID-19 pandemic and other events outside our control; our dependence upon our ability to respond to fluctuations in product demand; our ability to continually innovate, introduce new products timely, and successfully commercialize our innovations; failure to introduce new products in a timely manner; customer order timing and other similar factors may cause fluctuations in our operating results; disruptions or breaches in security of our and our third-party providers’ information technology systems; our failure to comply with data privacy regulations; changes in interest rates, credit ratings or foreign currency exchange rates; risks associated with our operations in foreign countries; our increased use of outsourcing in foreign countries; risks associated with increased outsourcing of components manufacturing; our exposure to increased tariffs, trade restrictions or taxes on our products; the continuing impact of “Brexit”; violations of our intellectual property rights and our ability to protect our intellectual property against infringement by third parties; risk of losing our competitive advantage; our failure to successfully integrate recent and future acquisitions into our business; our ability to attract and retain key personnel; our restructuring and realignment activities and disruptions to our operations as a result of consolidation of our operations; product defects or problems integrating our products with other vendors’ products; disruptions in the supply of certain key components or other goods from our suppliers; our failure to accurately forecast component and raw material requirements leading to excess inventories or delays in the delivery of our products; production difficulties and product delivery delays or disruptions; our exposure to medical device regulations, which may impede or hinder the approval or sale of our products and, in some cases, may ultimately result in an inability to obtain approval of certain products or may result in the recall or seizure of previously approved products; potential penalties for violating foreign, U.S. federal, and state healthcare laws and regulations; impact of healthcare industry cost containment and healthcare reform measures; changes in governmental regulations affecting our business or products; our failure to implement new information technology systems and software successfully; our failure to realize the full value of our intangible assets; increasing scrutiny and changing expectations from investors, customers, and governments with respect to Environmental, Social and Governance policies and practices; our reliance on original equipment manufacturer customers; being subject to U.S. federal income taxation even though we are a non-U.S. corporation; changes in tax laws, and fluctuations in our effective tax rates; our exposure to the credit risk of some of our customers and in weakened markets; any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance our existing indebtedness, which may not be available on acceptable terms or at all; our existing indebtedness limiting our ability to engage in certain activities; volatility in the market price for our common shares; and our failure to maintain appropriate internal controls in the future.
Other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition are discussed in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as updated by our subsequent filings with the Securities and Exchange Commission. Such statements are based on the Company’s beliefs and assumptions and on information currently available to the Company. The Company disclaims any obligation to publicly update or revise any such forward-looking statements as a result of developments occurring after the date of this document except as required by law.
About Novanta
Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary technology expertise and competencies in photonics, vision, and precision motion with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to our customers’ demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation and customer success. Novanta’s common shares are quoted on Nasdaq under the ticker symbol “NOVT.”
More information about Novanta is available on the Company’s website at www.novanta.com. For additional information, please contact Novanta Investor Relations at (781) 266-5137 or [email protected].
NOVANTA INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands of U.S. dollars or shares, except per share amounts)
(Unaudited)
Three Months Ended December 31,
Year Ended December 31,
2022
2021
2022
2021
Revenue
$
218,373
$
198,960
$
860,903
$
706,793
Cost of revenue
123,830
116,076
482,431
406,465
Gross profit
94,543
82,884
378,472
300,328
Operating expenses:
Research and development and engineering
21,904
19,418
85,770
72,522
Selling, general and administrative
38,710
34,966
158,901
129,155
Amortization of purchased intangible assets
5,351
5,277
26,338
16,577
Restructuring and acquisition related costs
1,734
1,535
4,384
18,020
Total operating expenses
67,699
61,196
275,393
236,274
Operating income
26,844
21,688
103,079
64,054
Interest income (expense), net
(5,688
)
(2,891
)
(15,616
)
(7,387
)
Foreign exchange transaction gains (losses), net
(2,240
)
172
67
(127
)
Other income (expense), net
19
(130
)
(371
)
(368
)
Income before income taxes
18,935
18,839
87,159
56,172
Income tax provision
3,673
5,085
13,108
5,841
Net income
$
15,262
$
13,754
$
74,051
$
50,331
Earnings per common share:
Basic
$
0.43
$
0.39
$
2.08
$
1.42
Diluted
$
0.42
$
0.38
$
2.06
$
1.41
Weighted average common shares outstanding—basic
35,738
35,485
35,652
35,396
Weighted average common shares outstanding—diluted
36,000
35,811
35,909
35,781
NOVANTA INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands of U.S. dollars)
(Unaudited)
December 31,
December 31,
2022
2021
ASSETS
Current Assets
Cash and cash equivalents
$
100,105
$
117,393
Accounts receivable, net
137,697
115,617
Inventories
167,997
125,657
Prepaid expenses and other current assets
14,720
15,158
Total current assets
420,519
373,825
Property, plant and equipment, net
103,186
87,439
Operating lease assets
43,317
48,338
Intangible assets, net
175,766
220,989
Goodwill
478,897
479,500
Other assets
19,527
17,792
Total assets
$
1,241,212
$
1,227,883
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Current portion of long-term debt
$
4,800
$
5,097
Accounts payable
75,225
68,514
Accrued expenses and other current liabilities
84,497
110,327
Total current liabilities
164,522
183,938
Long-term debt
430,662
429,361
Operating lease liabilities
40,808
45,700
Other long-term liabilities
27,634
47,593
Total liabilities
663,626
706,592
Stockholders’ Equity:
Total stockholders’ equity
577,586
521,291
Total liabilities and stockholders’ equity
$
1,241,212
$
1,227,883
NOVANTA INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands of U.S. dollars)
(Unaudited)
Three Months Ended December 31,
Year Ended December 31,
2022
2021
2022
2021
Cash flows from operating activities:
Net income
$
15,262
$
13,754
$
74,051
$
50,331
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
12,159
12,781
53,158
43,394
Share-based compensation
5,299
5,437
23,108
25,606
Deferred income taxes
(4,026
)
(881
)
(18,654
)
(3,945
)
Other non-cash items
1,441
1,847
3,853
6,248
Changes in assets and liabilities which provided/(used) cash, excluding effects from business acquisitions:
Accounts receivable
11,198
(3,897
)
(23,246
)
(25,355
)
Inventories
(1,995
)
(7,135
)
(48,547
)
(19,078
)
Other operating assets and liabilities
1,274
6,807
27,056
17,424
Net cash provided by operating activities
40,612
28,713
90,779
94,625
Cash flows from investing activities:
Acquisition of businesses, net of cash acquired and working capital adjustments
—
453
(21,565
)
(284,728
)
Purchases of property, plant and equipment
(4,258
)
(5,217
)
(19,643
)
(19,976
)
Other investing activities
—
200
(1,333
)
(2,000
)
Net cash used in investing activities
(4,258
)
(4,564
)
(42,541
)
(306,704
)
Cash flows from financing activities:
Borrowings under revolving credit facilities
—
—
69,941
280,000
Repayments under term loan and revolving credit facilities
(21,238
)
(8,345
)
(59,029
)
(32,381
)
Repurchases of common shares
—
—
(10,000
)
—
Payments of contingent consideration related to acquisitions
—
—
(46,254
)
(1,836
)
Other financing activities
(2,247
)
(1,192
)
(14,812
)
(41,030
)
Net cash used in financing activities
(23,485
)
(9,537
)
(60,154
)
204,753
Effect of exchange rates on cash and cash equivalents
2,656
386
(5,372
)
(335
)
Increase (decrease) in cash and cash equivalents
15,525
14,998
(17,288
)
(7,661
)
Cash and cash equivalents, beginning of period
84,580
102,395
117,393
125,054
Cash and cash equivalents, end of period
$
100,105
$
117,393
$
100,105
$
117,393
Contacts
Novanta Inc.
Investor Relations Contact:
Ray Nash
(781) 266-5137